Association of Vitamin D Levels and Risk of Ovarian Cancer: a Mendelian Randomization Study

Background: In vitro and observational epidemiological studies suggest that vitamin D may play a role in cancer prevention. However, the relationship between vitamin D and ovarian cancer is uncertain, with observational studies generating conflicting findings. A potential limitation of observational studies is inadequate control of confounding. To overcome this problem, we used Mendelian randomization (MR) to evaluate the association between single nucleotide polymorphisms (SNPs) associated with circulating 25-hydroxyvitamin D [25(OH)D] concentration and risk of ovarian cancer.

Methods: We employed SNPs with well-established associations with 25(OH)D concentration as instrumental variables for MR: rs7944926 (DHCR7), rs12794714 (CYP2R1) and rs2282679 (GC). We included 31 719 women of European ancestry (10 065 cases, 21 654 controls) from the Ovarian Cancer Association Consortium, who were genotyped using customized Illumina Infinium iSelect (iCOGS) arrays. A two-sample (summary data) MR approach was used and analyses were performed separately for all ovarian cancer (10 065 cases) and for high-grade serous ovarian cancer (4121 cases).

Results: The odds ratio for epithelial ovarian cancer risk (10 065 cases) estimated by combining the individual SNP associations using inverse variance weighting was 1.27 (95% confidence interval: 1.06 to 1.51) per 20 nmol/L decrease in 25(OH)D concentration. The estimated odds ratio for high-grade serous epithelial ovarian cancer (4121 cases) was 1.54 (1.19, 2.01).

Conclusions: Genetically lowered 25-hydroxyvitamin D concentrations were associated with higher ovarian cancer susceptibility in Europeans. These findings suggest that increasing plasma vitamin D levels may reduce risk of ovarian cancer.

Citing Articles

Predicted 25-hydroxyvitamin D over the adult lifetime and the risk of ovarian cancer.

Ritonja J, Danieli C, Pana M, Palmer M, LEsperance K, Ho V Am J Epidemiol. 2024; 193(9):1233.

PMID: 38754871 PMC: 11369219. DOI: 10.1093/aje/kwae070.

Vitamin D and reproductive disorders: a comprehensive review with a focus on endometriosis.

Farhangnia P, Noormohammadi M, Delbandi A Reprod Health. 2024; 21(1):61.

PMID: 38698459 PMC: 11064344. DOI: 10.1186/s12978-024-01797-y.

Phenomewide Association Study of Health Outcomes Associated With the Genetic Correlates of 25 Hydroxyvitamin D Concentration and Vitamin D Binding Protein Concentration.

Kresge H, Blostein F, Goleva S, Albinana C, Revez J, Wray N Twin Res Hum Genet. 2024; 27(2):69-79.

PMID: 38644690 PMC: 11138239. DOI: 10.1017/thg.2024.19.

Identification and validation of DHCR7 as a diagnostic biomarker involved in the proliferation and mitochondrial function of breast cancer.

Wang Y, Fan J, Liu Y, Du J, Liang B, Wang H Aging (Albany NY). 2024; 16(7):5967-5986.

PMID: 38526324 PMC: 11042931. DOI: 10.18632/aging.205683.

The Use of Lipid-based Nanocarriers to Improve Ovarian Cancer Treatment: An Overview of Recent Developments.

Tantray J, Patel A, Prajapati B, Kosey S, Bhattacharya S Curr Pharm Biotechnol. 2024; 25(17):2200-2217.

PMID: 38357950 DOI: 10.2174/0113892010279572240126052844.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Prescott J, Bertrand K, Reid B, Permuth-Wey J, De Vivo I, Cramer D . Evidence of differential effects of vitamin d receptor variants on epithelial ovarian cancer risk by predicted vitamin d status. Front Oncol. 2014; 4:286. PMC: 4202710. DOI: 10.3389/fonc.2014.00286. View

Sheehan N, Didelez V, Burton P, Tobin M . Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 2008; 5(8):e177. PMC: 2522255. DOI: 10.1371/journal.pmed.0050177. View

Lu Y, Cuellar-Partida G, Painter J, Nyholt D, Morris A, Fasching P . Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet. 2015; 24(20):5955-64. PMC: 4581608. DOI: 10.1093/hmg/ddv306. View

Afzal S, Brondum-Jacobsen P, Bojesen S, Nordestgaard B . Vitamin D concentration, obesity, and risk of diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2014; 2(4):298-306. DOI: 10.1016/S2213-8587(13)70200-6. View

J Malloy P, Feldman D . Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am. 2010; 39(2):333-46, table of contents. PMC: 2879401. DOI: 10.1016/j.ecl.2010.02.004. View

Tworoger S, Lee I, Buring J, Rosner B, Hollis B, Hankinson S . Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(4):783-8. DOI: 10.1158/1055-9965.EPI-06-0981. View

Theodoratou E, Palmer T, Zgaga L, Farrington S, McKeigue P, Din F . Instrumental variable estimation of the causal effect of plasma 25-hydroxy-vitamin D on colorectal cancer risk: a mendelian randomization analysis. PLoS One. 2012; 7(6):e37662. PMC: 3368918. DOI: 10.1371/journal.pone.0037662. View

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M . Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. DOI: 10.1038/nbt1210-1248. View

10.

Afzal S, Brondum-Jacobsen P, Bojesen S, Nordestgaard B . Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ. 2014; 349:g6330. PMC: 4238742. DOI: 10.1136/bmj.g6330. View

11.

Marchini J, Howie B, Myers S, McVean G, Donnelly P . A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet. 2007; 39(7):906-13. DOI: 10.1038/ng2088. View

12.

Burgess S, Scott R, Timpson N, Davey Smith G, Thompson S . Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015; 30(7):543-52. PMC: 4516908. DOI: 10.1007/s10654-015-0011-z. View

13.

Trummer O, Pilz S, Hoffmann M, Winkelmann B, Boehm B, Marz W . Vitamin D and mortality: a Mendelian randomization study. Clin Chem. 2013; 59(5):793-7. DOI: 10.1373/clinchem.2012.193185. View

14.

Walentowicz-Sadlecka M, Sadlecki P, Walentowicz P, Grabiec M . [The role of vitamin D in the carcinogenesis of breast and ovarian cancer]. Ginekol Pol. 2013; 84(4):305-8. DOI: 10.17772/gp/1581. View

15.

Ingraham B, Bragdon B, Nohe A . Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin. 2007; 24(1):139-49. DOI: 10.1185/030079908x253519. View

16.

Krishnan A, Feldman D . Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 2010; 51:311-36. DOI: 10.1146/annurev-pharmtox-010510-100611. View

17.

Mokry L, Ross S, Ahmad O, Forgetta V, Davey Smith G, Goltzman D . Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med. 2015; 12(8):e1001866. PMC: 4549308. DOI: 10.1371/journal.pmed.1001866. View

18.

Pharoah P, Tsai Y, Ramus S, Phelan C, Goode E, Lawrenson K . GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013; 45(4):362-70, 370e1-2. PMC: 3693183. DOI: 10.1038/ng.2564. View

19.

Cook L, Neilson H, Lorenzetti D, Lee R . A systematic literature review of vitamin D and ovarian cancer. Am J Obstet Gynecol. 2010; 203(1):70.e1-8. DOI: 10.1016/j.ajog.2010.01.062. View

20.

Arslan A, Clendenen T, Koenig K, Hultdin J, Enquist K, Agren A . Circulating vitamin d and risk of epithelial ovarian cancer. J Oncol. 2009; 2009:672492. PMC: 2735000. DOI: 10.1155/2009/672492. View